Conference Coverage
Baricitinib shows encouraging phase III results in RA
In the latest of a series of studies, baricitinib was more effective than placebo, and in most cases, than adalimumab, in achieving rapid...
Dr. Fleischmann reported serving as a paid researcher for and/or consultant to numerous pharmaceutical companies, including most of those developing Jakinibs.
